All the News

HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001

An Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis

@haya 20 May '26

HAYA's CEO Samir Ounzain Recognized as One of the In Vivo’s 2026 Rising Leaders

Citeline – In Vivo

@haya 14 Apr '26

Switzerland's Leading Innovators 2026

SIQT – Schweizer Institut für Qualitätstests GmbH

@haya 27 Jan '26

NextGen: Class of 2026

BioSpace

@haya 7 Jan '26

HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs®

To Accelerate Development of RNA-Guided Therapeutics Platform

@haya 3 Jun '25

HAYA Therapeutics Raises $65 Million in Series A Funding

To Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases

@haya 8 May '25

Upcoming Events (02)

Let’s Connect

ESC 2026

Meet Jordan Shin, CMO

Munich

Fri. 28 – Mon. 31 aug '26

ECCB 2026

Meet Samir Ounzain, CEO & Co-Founder

Sep

Geneva

Mon. 31 aug – Fri. 4 sep '26

Filter Categories

View All

Blog

Press Releases

News

Podcasts

Events

ECCB 2026

Meet Samir Ounzain, CEO & Co-Founder

Sep

Geneva

Mon. 31 aug – Fri. 4 sep '26

ESC 2026

Meet Jordan Shin, CMO

Munich

Fri. 28 – Mon. 31 aug '26

HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001

An Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis

@haya 20 May '26

HAYA's CEO Samir Ounzain Recognized as One of the In Vivo’s 2026 Rising Leaders

Citeline – In Vivo

@haya 14 Apr '26

HAYA’s Dark Genome Play: Turning ‘Junk DNA’ Into Drug Targets

Citeline

@haya 6 Apr '26

The cryptic messages of our genome

Technology Outlook

@haya 3 Feb '26

Switzerland's Leading Innovators 2026

SIQT – Schweizer Institut für Qualitätstests GmbH

@haya 27 Jan '26